MS is a frequently disabling autoimmune disease affecting approximately 350,000 people in the United States. It is among the most disabling diseases in the United States, with 81% of all patients out of the workforce. More that two decades of research has consistently shown a relationship between stressful life events (SLEs), in particular non-traumatic family and work stressors, and subsequent clinical exacerbation. Furthermore, we have shown that non-traumatic SLEs increase the risk of the subsequent appearance of new gadolinium enhancing (Gd+) magnetic resonance imaging (MRI) brain lesions, an early marker of MS inflammation and blood-brain barrier (BBB' breakdown. The purpose of this study is to determine the efficacy of cognitive behavioral therapy for MS (CBT. MS), a stress management program we have developed specifically for MS, in reducing the occurrence of new brain lesions in people with relapsing-remitting multiple sclerosis (RRMS). RRMS was selected over other types, because it is the most common form of MS and it is more likely than other types to be associated with clinical exacerbation and Gd+ MRI. One hundred and twelve patients will be enrolled for 2 years. To ensure equivalent medical treatment across patients and treatment arms, all patients will receive neurological care through the University of California, San Francisco (UCSF) MS Center. Patients will be randomly assigned to either CBT-MS or treatment as usual (TAU). The stress management program will consist of 26 weekly group stress management training sessions followed by 12 monthly booster sessions to encourage maintenance of behavioral changes, Because MS exacerbation is episodic, with annual prevalence rates of .61 - 1.68, longer maintenance of behavioral changes will greatly increase the power to detect effects. Patients will be followed for 6 months following cessation of treatment and booster sessions. To encourage retention, TAU patients will be offered 26 weeks of CBT-MS after completing the study. Consistent with Phase II clinical trials in MS, the primary outcome will be Gd+ MRI brain lesions acquired at screening, and months 3, 6, 12, 18, and 24. Secondary neuroimaging outcomes will include T2-weighted MRI and brain parenchymal fraction (BPF). Secondary clinical outcomes will include MS exacerbation rate, progression of disability, and neuropsychological impairment. Quality of life will be examined as a secondary outcome to evaluate clinical utility. We also wilt enhance our understanding of mechanisms by examining potential psychosocial, immune, and endocrine mediators of the relationship betweenSLEs and clinical and neuroimaging markers of MS inflammation.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD043323-02
Application #
6796869
Study Section
Special Emphasis Panel (ZRG1-RPHB-3 (01))
Program Officer
Quatrano, Louis A
Project Start
2003-09-01
Project End
2008-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
2
Fiscal Year
2004
Total Cost
$1,504,369
Indirect Cost
Name
Northern California Institute Research & Education
Department
Type
DUNS #
613338789
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Gold, Stefan M; O'Connor, Mary-Frances; Gill, Raja et al. (2014) Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling. Hum Brain Mapp 35:30-7
Burns, M N; Nawacki, E; Kwasny, M J et al. (2014) Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis? Psychol Med 44:349-59
Burns, Michelle Nicole; Nawacki, Ewa; Siddique, Juned et al. (2013) Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med 75:76-82
Lehman, Kenneth A; Burns, Michelle Nicole; Gagen, Emily C et al. (2012) Development of the brief inventory of perceived stress. J Clin Psychol 68:631-44
Mohr, David C; Lovera, Jesus; Brown, Ted et al. (2012) A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology 79:412-9
Baron, Kelly Glazer; Corden, Marya; Jin, Ling et al. (2011) Impact of psychotherapy on insomnia symptoms in patients with depression and multiple sclerosis. J Behav Med 34:92-101
Cosio, David; Jin, Ling; Siddique, Juned et al. (2011) The effect of telephone-administered cognitive-behavioral therapy on quality of life among patients with multiple sclerosis. Ann Behav Med 41:227-34
Grossman, P; Kappos, L; Gensicke, H et al. (2010) MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 75:1141-9
Julian, L J; Vella, L; Frankel, D et al. (2009) ApoE alleles, depression and positive affect in multiple sclerosis. Mult Scler 15:311-5
Julian, Laura J; Vella, Lea; Vollmer, Tim et al. (2008) Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol 255:1354-60

Showing the most recent 10 out of 12 publications